Clincosm LogoSign in Get a demo

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Sponsor
Boehringer Ingelheim (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05916313
Collaborator
(none)
35
Enrollment
2
Arms
26.5
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.

The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer.

Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is continued. During this time, participants visit the study site at regular intervals. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include staying to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.

Condition or Disease Intervention/Treatment Phase
  • Drug: BI 764532
 Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
35 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase Ib Open-label, Multi-center, Dose Escalation Trial of BI 764532 Given as Monotherapy Administered by Repeated Intravenous Infusions in Patients With Glioma Expressing DLL3
Anticipated Study Start Date :
Sep 7, 2023
Anticipated Primary Completion Date :
Oct 17, 2025
Anticipated Study Completion Date :
Nov 21, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: BI 764532: Part A - Dose escalation cohort

Drug: BI 764532
BI 764532
Experimental: BI 764532: Part B - Dose expansion cohort

Drug: BI 764532
BI 764532

Outcome Measures

Primary Outcome Measures

  1. Part A: Occurrence of dose-limiting toxicity (DLT) during the maximum tolerated dose (MTD) evaluation period [up to 4 weeks]

  2. Part B: Occurrence of dose-limiting toxicity (DLT) during the entire treatment period [up to 14 months]

Secondary Outcome Measures

  1. Part A: Occurrence of dose-limiting toxicity (DLT) during the entire treatment period [up to 26 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the first informed consent form (ICF1).

  2. Signed and dated written informed consent (ICF1 and ICF2) in accordance with International Council for Harmonisation-Good clinical practice (ICH-GCP) and local legislation prior to admission to the trial.

  3. Patients with histologically confirmed primary progressive diffuse glioma who have failed standard of care therapies.

  4. Availability of archival tumour tissue for Delta-like 3 (DLL3) expression by central assessment.

  5. Tumours must be positive for DLL3 expression by immunohistochemistry (IHC) on archived tumour tissue according to central pathology review.

  6. Documented unequivocal progression after radiotherapy and/or chemotherapy with measurable disease by response assessment in neuro-oncology (RANO) criteria.

  7. Karnofsky performance score ≥70. Further inclusion criteria apply.

Exclusion Criteria:

  1. Previous treatment in this trial.

  2. Current enrolment in another investigational device or drug trial.

  3. Presence of extracranial metastatic or leptomeningeal disease.

  4. Previous treatment with therapies targeting DLL3.

  5. Prior treatment with bevacizumab or other anti-vascular endothelial growth factor (anti-VEGF) or anti-angiogenic treatment within 6 months prior to first administration of BI 764532.

  6. Recent anti-cancer therapy: treatment with any other anticancer drug within 21 days or within 5 half-life periods (whichever is shorter) prior to first administration of BI

  8. Radiotherapy within the 3 months prior to the diagnosis of progression; unless tumour progression is clearly outside the radiation field or tumour progression is unequivocally proven by surgery/biopsy.

Further exclusion criteria apply.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Boehringer Ingelheim

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT05916313
Other Study ID Numbers:
  • 1438-0003
  • U1111-1290-7234
  • 2022-501766-22-00
First Posted:
Jun 23, 2023
Last Update Posted:
Jun 23, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Glioma

Study Results

No Results Posted as of Jun 23, 2023